Sight Sciences announced it will debut the Omni Edge Surgical System at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in Los Angeles. The system is intended for the treatment of primary open-angle glaucoma and can be used alone or with cataract surgery. It treats all 3 main outflow resistance points in the eye: the trabecular meshwork, Schlemm’s canal, and the collector channels.

Omni Edge builds on the design of the Omni Surgical System with the addition of TruSync technology, which allows synchronized deployment of viscoelastic material through 360º of Schlemm’s canal. The device nearly doubles the delivery capacity to 21 µL while maintaining the ergonomics and safety features of its predecessor.

Omni Edge is available only in the United States and is designed as a single-use device. Physicians and attendees can preview the new system on April 26 at the ASCRS meeting. The system expands Sight Sciences’s portfolio of implant-free devices for minimally invasive glaucoma surgery (MIGS). GP